Parexel technology improves late phase study efficiency
Brings greater cost-effectiveness to large-scale studies
Parexel, a global biopharmaceutical services provider, has introduced a web-based technology platform for late phase clinical research to meet the expanding regulatory and commercialisation needs of the biopharmaceutical industry. The company says it will bring greater cost-effectiveness to large-scale studies and facilitates efficient capture of global safety and health outcomes data.
The solution integrates Parexel's PACE (Peri Approval Clinical Excellence) team with eClinical solutions from Perceptive Informatics, Parexel's technology subsidiary.
‘We are focused on helping clients achieve greater efficiency by gathering more data at a significantly lower cost per patient,’ said Carol Collins, corporate vice president and worldwide head of PACE at Parexel. ‘This new technology platform reinforces our commitment to assist clients in generating more robust product safety and heath outcomes profiles.’
The platform offers a streamlined user experience with single access; an intuitive interface; automated cues for late phase site requirements to enable improved compliance; enhanced reporting capabilities and centralised access to data including site, patient, and clinical supply information.
